MedTrace Logo

Immunologic Signatures Following Surgery for Pancreatic Cancer

NCT03001518 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 33

Last updated 2023-06-28

No results posted yet for this study

Summary

The goal of this pilot study is to evaluate and describe the immunologic and overall outcomes of subjects who undergo routine pancreatectomy with or without irreversible electroporation (IRE) for pancreatic cancer. Immunologic markers in the blood will be measured at several time points before and after surgery to determine if surgical approach is associated with different immunologic responses. Secondary outcomes will include mortality and morbidity; operative time; blood loss and transfusion requirements; and oncologic outcomes such as: margin status, lymph node harvest, disease-free survival, and overall survival. Analysis of immune response will help the investigator determine whether to expand the pilot into a larger study.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Sabino Zani, MD · Duke Health

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-04
Primary Completion
2021-01-07
Completion
2023-01-06

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03001518 on ClinicalTrials.gov